Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | ADK | P55263 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.31 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18656780 | 0.87 | MEN1 (0.35) | MEN1NR2F2KMT2ADYRK1AADK | |
| SCHEMBL18656782 | 0.83 | MEN1 (0.33) | MEN1NR2F2KMT2ADYRK1AADK | |
| SCHEMBL18341927 | 0.80 | RET (0.37) | MEN1NR2F2KMT2AADKADORA2A | |
| SCHEMBL18656761 | 0.78 | MEN1 (0.41) | MEN1NR2F2KMT2ADYRK1AADK | |
| SCHEMBL20492598 | 0.77 | ADORA2A (0.40) | MEN1NR2F2KMT2AADKADORA2A | |
| SCHEMBL18342055 | 0.76 | MEN1 (0.60) | MEN1NR2F2KMT2ASRCADORA2A | |
| SCHEMBL20493241 | 0.76 | MEN1 (0.50) | MEN1NR2F2KMT2AADORA2AADORA2B | |
| SCHEMBL18341958 | 0.74 | MEN1 (0.48) | MEN1NR2F2KMT2AADORA2AADORA2B | |
| SCHEMBL18341924 | 0.72 | ALDH1A1 (0.46) | MEN1NR2F2KMT2A | |
| SCHEMBL18341932 | 0.70 | CYP2C19 (0.43) | MEN1NR2F2KMT2ASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137497-B | Bicyclic derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-06-15 | — | — | CN | disclosed |
| EP-3313817-B1 | BICYCLIC DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2020-09-16 | — | — | EP | disclosed |
| US-10618909-B2 | Bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2020-04-14 | — | — | US | disclosed |
| US-20190248805-A1 | BICYCLIC DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2019-08-15 | — | — | US | disclosed |
| US-10323041-B2 | Bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2019-06-18 | — | — | US | disclosed |
| US-20180258098-A1 | BICYCLIC DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2018-09-13 | — | — | US | disclosed |
| EP-3313817-A1 | NEW BICYCLIC DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Les Laboratoires Servier (FR) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016207217-A1 | NEW BICYCLIC DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618909-B2 | Bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them | BAX, CASP3, CASP4 | MEN1 3032/4885NR2F2 2975/4885KMT2A 4328/4885 |
| US-20180258098-A1 | BICYCLIC DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BAX, CASP3, CASP4 | MEN1 3120/4885NR2F2 2980/4885KMT2A 4358/4885 |
| US-20190248805-A1 | BICYCLIC DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BAX, CASP3, CASP4 | MEN1 3032/4885NR2F2 2975/4885KMT2A 4328/4885 |
| US-10323041-B2 | Bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them | BAX, CASP3, CASP4 | MEN1 3032/4885NR2F2 2975/4885KMT2A 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.